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Prediction of asymptomatic abdominal aortic
aneurysm expansion by means of rate of variation
of C-reactive protein plasma levels
Joaquin De Haro, MD,a Francisco Acin, MD, PhD,a Silvia Bleda, MD,a Cesar Varela, MD,a
Francisco J. Medina, MD,a,b and Leticia Esparza, MD,a Madrid and Burgos, Spain
Objective: C-reactive protein (CRP) is an independent risk factor for arteriosclerosis, but its role in abdominal aortic
aneurysm (AAA) expansion remains not completely verified. There are no data about the prognostic significance of rates
of variation of the CRP levels in asymptomatic AAAs. This study investigated the association between plasma CRP levels
and AAA diameter and assessed the relationship between the gradient of CRP levels and rates of expansion in
asymptomatic AAAs.
Methods: Plasma levels of high-sensitive CRP (hs-CRP) were measured using a high-sensitivity technique and AAA size was
determined by computed tomography in 435 patients with asymptomatic AAAs followed up in our outpatient department.
Results:Themedian hs-CRP level was 4.23mg/L. The aorta diameter increased in the four groups of patients determined
according to hs-CRP quartiles (35 2, 40 3, 49 4, and 58 5mm; P .01). The median rate of CRP level variation
per year was 1.4 mg/L. Patients with an elevation>1.4 mg/L had an expansion rate of 4.8 mm vs 3.9 mm in those<1.4
mg/L (P< .01). The multivariate age-adjusted logistic model confirmed initial diameter and variation of CRP level were
the only factors associated with expansion, with odds ratios (95% confidence intervals) of 6.3 (3.1-7.5) and 3.4 (2.1-5.6).
Conclusions: These results confirm a statistical association between AAA diameter and hs-CRP plasma levels. This cohort
study corroborates this potential causal association and contributes information about the value of the hs-CRP plasma
level gradient as a marker of disease progression and rate of expansion. (J Vasc Surg 2012;56:45-52.)
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MThe degenerative form of abdominal aortic aneurysm
(AAA) is a chronic disease of the medial layer of the aorta
characterized by dilation due to degradation of the compo-
nents of the extracellular matrix and thinning of the me-
dia.1 Inflammatory processes appear to be important in the
formation of this type of aneurysm, as shown by the exten-
sive inflammatory cell infiltrates found in histologic samples
of the media and adventitia of macroscopic degenerative
aneurysmal aorta walls.2 Accordingly, we can also find
increased expression of proinflammatory cytokines in aneu-
rysmal tissues3-7 and higher plasma levels of inflammatory
cytokines in patients with AAAs.8,9 The serum concentra-
tion of various cytokines is associated with the diameter of
the aneurysm (interleukin-8),8 AAA symptoms (tumor ne-
crosis factor-),8 and the rate of expansion of the AAA
(interferon-).9
C-reactive protein (CRP) has emerged as an indepen-
dent risk factor for arteriosclerosis and its associated com-
plications in apparently healthy individuals as well as in
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doi:10.1016/j.jvs.2012.01.003atients with cardiovascular disease.10-15 Two decades ago,
owell et al16 found that among patients undergoing elec-
ive aortic reconstruction, CRP plasma levels were higher in
atients with AAAs compared with those with obstructive
isease. Although there were later reports of elevated CRP
erum levels in patients with symptomatic or ruptured
AAs, this earlier observation of high levels in patients with
symptomatic AAAs was not completely verified17-20 nor
as the role of a sustained chronic inflammation, marked by
RP, in the AAA expansion. It remains unclear whether the
RP baseline plasma level is of any prognostic significance
n rate of expansion, and there are no data about the
rognostic significance of the rates of variation of the CRP
evels in asymptomatic AAAs. It is in the management of
mall (diameters of 30-54 mm) asymptomatic AAAs that this
ypothetic predictor of expansion might have a role in plan-
ing an early elective intervention, in those AAA patients who
eally may benefit from intervention, avoiding long and un-
ecessary periods of follow-up and uncertainty as well as in the
evelopment of strategies to prevent expansion.
Therefore, our study determined the plasma levels of
igh-sensitivity CRP (hs-CRP) plasma levels using high-
ensitivity measurements in patients with asymptomatic
AAs to study the association between plasma CRP levels
nd AAA diameter and assessed the relation between vari-
tion of CRP levels and rates of expansion of AAAs.
ETHODS
The study was approved by the local Ethics Committee.
ll the patients gave their informed consent.
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July 201246 De Haro et alPatients. This study included 435 asymptomatic AAA
patients being followed up at the outpatient service at the
Department of Angiology and Vascular Surgery at Getafe
University Hospital, or those admitted for elective surgical
or endovascular repair of their asymptomatic aneurysm, or
both, who met the size and growth rate criteria and indica-
tions for this procedure. The study excluded 79 patients
who had symptomatic or ruptured AAAs, recent infections,
active inflammatory processes, fever, recent trauma, malig-
nant diseases, surgical operations 45 days, and CRP
plasma levels 10 mg/L. The main causes, among these
stated, of exclusion were symptomatic or ruptured AAAs,
active inflammatory processes, and malignant diseases.
Only three patients (AAA diameters of 36, 41, and 39 mm)
were excluded because of CRP plasma levels 10 mg/L
not justified by any of the other causes listed.
Demographic data and medical history of each patient
were collected, especially regarding cardiovascular risk fac-
tors, history of any relevant disease, concomitant diseases,
medication, and current clinical condition. At inclusion,
260 patients did not meet surgical or endovascular criteria
for elective AAA repair and were scheduled to attend a
follow-up protocol visit involving repeat AAA diameter size
assessment by computed tomography (CT) scan and CRP
plasma level measurement at 12 months, according to
protocol. All of these patients were available for the
follow-up visit at 12 months.
Measurement of the AAA diameter. An axial CT
angiography (CTA) scan was performed on all enrolled
patients to determine the maximum transversal diameter of
the AAA at the inclusion visit and in the follow-up. All
patients whose CT scans showed aneurysms with a saccular
morphology or signs of perianeurysmal inflammation were
excluded from the study.
Helical CT scans were performed on a Somatom Plus
(Siemens AGMedical Engineering, Forchheim, Germany).
Contrast scans were acquired after an antecubital intrave-
nous injection of 80 to 100 mL of a nonionic contrast
medium containing iodine (300 mg/mL). The helical CT
scan was performed with a delay of 20 to 25 seconds after
starting the injection. The tube detector unit was rotating
continuously at 1 to 1.3 rotations/s. Slice collimation was 5
mm, and table speed was 8 to 10 mm/s in the caudocranial
direction. Reconstruction was achieved every 1.3 mm with
the 180° linear interpolation algorithm.Multiplanar recon-
struction was generated on a Magic View Workstation
(Siemens Medical Systems, Erlangen, Germany). The slices
were manually adjusted for each aortic level to get an
oblique plane strictly perpendicular to the course of the
aorta. The internal diameter of the vessel was measured
with an electronic caliper in three directions at the point of
the maximum orthogonal diameter of the AAA. All images
were reconstructed and analyzed by an experienced, inde-
pendent, observer who was blinded for CRP levels.
Measurement of CRP plasma levels. Peripheral ve-
nous blood samples were obtained from patients when they
were included in the study and in the follow-up, if the case
proceeded. All the blood samples were obtained between u:00 to 10:00 A.M. Hemolyzed samples were discarded and
he patients were scheduled for a further adequate blood
ample the next day. Samples were centrifuged at 1500 rpm
or 10 minutes, and the plasma was stored at 20°C until
nalysis. CRP plasma concentrations were measured using
n automatic high-sensitivity immunoassay technique
Roche Diagnostics GMBH, Basel, Switzerland) with a
ower detection limit of 0.2 mg/L and a coefficient of
ariation of 4.2% in 4 mg/L and 6.3% in 1 mg/L.21
Also determined for each patient was a plasma lipid
rofile (consisting of the levels of total cholesterol, triglyc-
rides and high-density, low-density and very-low-density
ipoprotein), homocysteine plasma concentration, plasma
evels of creatinine and glycosylated hemoglobin (HbA1c),
nd a complete blood count.
Diagnostic criteria. Cardiovascular risk factors in-
luded smoking, hypertension, diabetes, and hyperlipid-
mia. Patients were considered nonsmokers if they did not
moke any cigarettes and were considered former smokers
f they had stopped smoking at least 6 months previously.
Patients were classified as being hypertensive when the
ystolic/diastolic blood pressure values were 140/90
m Hg or they took any type of antihypertensive medica-
ion.
Patients were considered to have diabetes mellitus if
hey presented with baseline glycemia (120 mg/dL) or
ere taking oral antidiabetic or insulin treatment.
Hyperlipidemia was defined as a plasma concentration
f total cholesterol240 mg/dL, triglyceride levels200
g/dL, or if the patient was taking hypolipidemic drugs.
Heart disease was considered present when the pa-
ient’s medical history confirmed previous myocardial in-
arction, a positive angiogram for coronary disease, or a
ositive isotopic test. Cerebrovascular disease was consid-
red present when the patient reported a history of ischemic
troke or stenosis of50% documented by duplex imaging
r arteriography in at least one carotid artery.
Sample size. The cohort size required to detect possi-
le differences in the CRP plasma levels and CRP variation
ates depending on the diameter of the AAA and rates of
xpansion of AAAwas determined based on the assumption
f a two-tailed  error of 0.05 and a statistical power of 0.8
or the prospective design, in accordance with the esti-
ated variances for each variable reported by previous
tudies in a population similar to that in our study.17 The
ample size estimated to perceive differences in the variable
baseline CRP plasma levels,” depending on the variable
AAA diameter,” was 243 patients. The sample size calcu-
ation for detecting any difference in the CRP variation rate
s a function of the AAA expansion rate was 196 patients.
Statistical analysis. Possible bivariate interaction be-
ween CRP and diameter was explored by using four
roups, divided into quartiles groups according to AAA
iameter or CRP levels. The Kruskal-Wallis test was used
or comparison of medians to analyze the hs-CRP values,
hich did not have a normal distribution but was skewed
oward higher values. The Kolmogorov-Smirnov test was
sed to check the normal distribution of the AAA diameter
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Volume 56, Number 1 De Haro et al 47in our population. Kruskal-Wallis test was used to find
differences between AAA diameters according to hs-CRP
levels. The univariate analysis was performed using analysis
of variance.
Amultivariate analysis included cardiovascular risk factors,
plasma markers for acute inflammation, anti-inflammatory or
antiplatelet medication, statins, and angiotensin-converting
enzyme (ACE) inhibitors to control for potential confound-
ing factors between the groups obtained in each analysis. A
correlation analysis using the Spearman  univariate test was
applied to hs-CRP and AAA diameter to demonstrate any
possible linear correlation between the two variables.
Subsequent analysis of the data began with calculation
of the change in size of the infrarenal aortic diameter in 12
months for all patients who attended the follow-up visit
(annual rate of aortic expansion). This absolute rate was
defined as the difference between the AAA diameter at 12
months and the baseline size. These measurements were
used to categorize AAAs into “rapid expanders” (more
than the median of expansion per year) and “slow expand-
ers” (less than the median of expansion per year). The
median of the annual rate of aortic expansion was 4.1 mm.
The rate of absolute variation of hs-CRP levels was
calculated as the difference between the hs-CRP value at
the 12-month follow-up visit minus the value when the
patient was included.
Contingency tables were constructed in which rapid
AAA expanders were compared with slow AAA expanders
across a range of independent factors that we hypothesized
would be associated with rates of expansion: age, initial
aortic diameter, smoking status, hypertension, diabetes
mellitus, hyperlipidemia, history of coronary heart disease,
stroke, or peripheral arterial disease, baseline and 12-month
levels of CRP, and variation of CRP level.
A post hoc analysis was performed to clear a potential
relation between AAA diameter and CRP levels that might
act as a confounder. The rate of AAA expansion and the rate
of hs-CRP variation were transformed in the relative rate of
AAA expansion and the relative rate of CRP variation as a
function to their basal values, respectively. Correlation
analyses among variables were applied.
All aortic diameter size assessments were performed on
CTA in the transverse section image of the maximum
diameter of the AAA. All measurements were performed
with the operators blinded to previous aortic diameter
measurements and CRP levels.
The data for variables with a normal distribution were
expressed as mean  the standard deviation and for non-
normal distribution as the median (25th percentile; 75th
percentile). Statistical analyses were performed using SPSS
16 software (SPSS Inc, Chicago, Ill). Statistical significance
was considered to be a value of P .05 in bilateral analysis.
RESULTS
The study included 435 patients, 69 of whom were
women (16%), with a mean age of 72.1  9.0 years. The
demographic characteristics are reported in Table I. In all,
75% were hypertensive, 18% had diabetes, 25% had hyper- rholesterolemia, 75% were smokers, 42% had chronic ob-
tructive pulmonary disease, and 72% had concomitant
cclusive arterial disease (coronary, cerebral, or in lower
imbs).
The 25th, 50th, and 75th percentiles of hs-CRP were
.31, 4.23, and 6.02 mg/L, respectively. The aorta diam-
ter increased in the four groups of patients determined
ccording to hs-CRP quartiles (35 2, 40 3, 494, and
8  5 mm; P  .01). Differences between the groups
ccording to the hs-CRP levels were statistically significant.
o significant differences were found among the variables
hat were potential confounding factors related to hs-CRP
uartiles (variable of interest; Table II). Plotting them on a
raph shows how these differences present a trend toward
n association between the two variables as the aorta diam-
ter increases in successive quartiles, from lower to higher,
f the plasma hs-CRP levels of the population (Fig 1).
When the patients were divided according to AAA
iameter into the respective quartiles (AAA 39, 39-47,
7-57, and 57 mm), the hs-CRP plasma values differed
mong these groups (2.0, 3.6, 5.3, and 7.8 mg/L, respec-
ively; P  .001), with the hs-CRP level increasing in each
roup with greater AAA size (Fig 2). There was therefore
lso a tendency toward positive association shown on the
rror bar graph. Similarly, no significant differences were
ound among potential confounders as a function of AAA
iameter (outcome of interest). Thus, these potential con-
ounders were not related to the outcome of interest or the
ariable of interest.
Finally, the size of the AAA had a linear correlation with
he hs-CRP plasma level (r  0.69; P  .05; Fig 3).
The analysis of rates of expansion and risk factors for
xpansion was based on 260 patients who attended a 12-
onth follow-up visit after inclusion but who did not meet
able I. Demographic characteristics
ariable
Mean  SD
or No. (%)
(N  435)
ean age, years 72.1  9.0
ale sex 366 (84)
ypertension 326 (75)
lood pressure, mm Hg
Systolic 148  21
Diastolic 85  17
yperlipidemia 105 (24)
otal cholesterol, mg/dL 189  33
riglycerides, mg/dL 166  41
iabetes mellitus 81 (18)
aseline glycemia, mg/dL 107  27
lycosylated hemoglobin, % 4.7  0.9
mokers 331 (76)
schemic heart disease 139 (32)
OPD 184 (42)
cute cerebrovascular accident 72 (16)
hronic lower limb ischemia 106 (24)
OPD, Chronic obstructive pulmonary disease; SD, standard deviation.epair criteria at inclusion.
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July 201248 De Haro et alThemedian annual rate of expansion was 4.1 mm, used
as the cutoff for patient grouping. The median (25th, 75th
quartile) CRP level rise in “rapid-expanders” patients was
Table II. Abdominal aortic aneurysm (AAA) diameter in
quartilesa
Variableb
25th
2.31 2
(n  109) (n
AAA diameter, mm 35  2 4
Age 72.5  8 72
Hypertension (%) 76 (69.7) 79
Blood pressure, mm Hg
Systolic 141  20 14
Diastolic 82  16 8
Hyperlipidemia 26 (24) 34
Diabetes 26 (24) 20
Smoking (%) 77 (70.6) 84
Chronic lower limb ischemia 33 (30.2) 28
Leukocytes, 103/	L 7734  1107 791
Log (creatinine), 
 10–3 4.3
Homocysteine, 	mol/L 11.23  3.8 10.7
Heart disease 32 (29.3) 31
Cerebrovascular disease 11 (10) 23
Treatment
Antiplatelet 49 (45) 50
Statins 39 (35.8) 43
ACE inhibitor 47 (43.1) 47
Calcium channel blocker 26 (23.8) 31
ACE, Angiotensin converting enzyme; SD, standard deviation.
aKruskal-Wallis test was used to analyze differences in AAA diameters. A
confounding factors when distributed by hs-CRP quartiles.
bContinuous data are shown as the mean  standard deviation and categor
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Fig 1. The error bar graph shows an increase in the abdominal
aortic aneurysm aorta (AAA) diameter (mm) according to quar-
tiles of high-sensitive C-reactive protein (hs-CRP) levels (mg/dL).
There were statistically significant differences among the groups
determined by Kruskal-Wallis test (P .01). The error bars repre-
sent the 95% confidence interval.1.8 (1.5; 1.9) mg/L compared with 1.0 (0.9; 1.2) mg/L in sslow expanders” (P  .001). The median (25th, 75th
uartile) rate of CRP level variation per year was 1.4 (1.2;
.6) mg/L. Patients with an elevation above 1.4 mg/L had
n expansion rate of 4.8  0.5 vs 3.9  0.4 mm of those
1.4 mg/L (P  .01). Fig. 4 shows the correlation be-
ween baseline AAA diameter and absolute rate of expan-
ion to high-sensitive C-reactive protein (hs-CRP)
CRP percentiles, mg/L
P
75th 100
23 4.23-6.01 6.01
9) (n  109) (n  108)
49  4 58  5 .01
71.8  8 70.5  9 .95
.5) 85 (78) 86 (79.6) .64
0 147  22 149  24 .55
7 85  19 86  18 .23
.2) 30 (27.5) 15 (13.8) .53
.3) 19 (14.7) 16 (14.7) .87
) 89 (81.6) 81 (75) .69
.6) 24 (22) 21 (19.4) .77
478 7979  1620 7863  1722 .99
15 4.3 .33
.2 11.68  3.5 12.12  4.2 .87
.4) 37 (34) 39 (36.1) .72
.1) 26 (23.8) 12 (11) .41
.8) 56 (51.4) 57 (52.7) .81
.4) 46 (42.2) 44 (40.7) .52
.1) 53 (48.63) 55 (50.1) .86
.4) 38 (34.8) 26 (24) .78
-of-variance test was used to find significant differences in the potential
as number (%).
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ig 2. The error bar graph shows an increase in the high-sensitive
-reactive protein (hs-CRP) levels log transformation according to
bdominal aortic aneurysm (AAA) diameter (mm) quartiles.
here were statistically significant differences among groups deter-
ined by Kruskal-Wallis test (P  .001). The error bars represent
5% confidence interval.relat
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Volume 56, Number 1 De Haro et al 49absolute rate of CRP increase and the absolute rate of AAA
expansion (r  0.71; P  .05).
After adjusting for age, univariate analysis revealed a
0
10
20
30
40
50
60
70
80
90
0 2 4 6 8 10 12
hsPCR(mg/L)
A
A
A
 d
ia
m
et
er
(m
m
)
Fig 3. The relation is shown between high-sensitive C-reactive
protein (hs-CRP) levels and abdominal aortic aneurysm (AAA)
diameter, with the linear correlation derived by the Spearman  test
(r  0.69; P  .05).
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Fig 4. A, Correlation between baseline abdominal aortic aneu-
rysm (AAA) size and absolute rate of AAA expansion (r  0.63;
P  .05). B, Correlation between absolute rate of C-reactive
protein (CRP) increase and absolute rate of AAA expansion (r 
0.71; P  .05).significant association between initial aortic diameter and pncreased hs-CRP levels with an annual expansion rate
4.1 mm (Table III).
There was no association with baseline and 12-month
s-CRP levels, hypertension, smoking status, diabetes mel-
itus, hyperlipidemia, history of coronary heart disease,
troke, or peripheral arterial disease.
The multivariate age-adjusted logistic model-confirmed
nitial diameter and variation of CRP level were the only
actors associated with expansion, with odds ratios (95% con-
dence intervals) of 6.3 (3.1-7.5) and 3.4 (2.1-5.6).
To totally control the potential confounding relation
etween initial AAA size and baseline hs-CRP levels with
he rate of AAA expansion and the variation of hs-CRP
evels, a transformation of the variable rate of AAA expan-
ion and gradient of hs-CRP levels was performed accord-
ng to the baseline AAA diameter and baseline hs-CRP
evels, respectively, to relativize the absolute ratio variables
s a function of the baseline variables. The transformation
sed to calculate the relative rate of AAA expansion was:
(12-month AAA size – initial AAA size)/initial AAA size)
100%]. And for the relative rate of hs-CRP increase:
(12-month hs-CRP level – baseline hs-CRP level/baseline
s-CRP level) 
 100%].
No significant correlation was found between baseline
AA size and relative rate AAA expansion (r  0.31; P 
05) and between basal CRP levels and the relative rate of
AA diameter variation (r  0.33; P  .05). The only
orrelation evidenced was between the relative rate of CRP
ariation and the relative rate of AAA expansion (r 0.62;
 .05; Fig 5).
This post hoc analysis shows the potential relation
etween AAA diameter and CRP levels and disclaims it as a
onfounder. Thus, this analysis revealed that the only inde-
endent factors that were proved related to AAA expan-
ion, and subsequently to the rupture risk, were the AAA
iameter and the rate of variation of hs-CRP.
ISCUSSION
The implication of chronic inflammatory processes in
he etiopathogenic origin of arteriosclerotic disease has
lready been demonstrated. Patients with occlusive arterio-
clerotic disease have moderately elevated plasma CRP
evels, and these levels are associated in turn with a greater
isk of developing cardiovascular events.11-15 Previous
tudies showed that the clinical severity of peripheral artery
isease is linearly associated with these elevated plasma
RP levels.10 Nevertheless, there is little information about
he possible common inflammatory origin of occlusive
isease and aneurysmal disorders. This would suggest that
hronic systemic inflammatory mechanisms similar to those
elated to the formation of arteriosclerotic plaques are
nvolved in the formation of degenerative aneurysms. To
ate, there is not enough information regarding acute-
hase inflammatory markers in patients with aneurysmal
isease.
Powell et al16 found that plasma CRP levels were
igher in patients with asymptomatic AAAs than in those of
atients with occlusive pathologies waiting for surgical
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July 201250 De Haro et alaortic repair. They reported a mean CRP serum level of
56 10 mg/L in patients with aneurysms. An explanation
for such high figures could be that a high-sensitivity
method was not used to measure CRP or that the study
included patients with acute inflammatory processes.
Recent studies show that patients with ruptured or
symptomatic AAAs have higher CRP levels than patients
with asymptomatic AAAs. These results can be explained by
the acute inflammatory processes that take place at the time
of the rupture and the resulting cascade of homeostatic
events that the body uses to overcome a hemodynamic
situation with the magnitude of a ruptured AAA.
Norman et al17 found in a prospective cohort study of
545 men with small aneurysms, monitored for a median of
48 months, that baseline CRP levels were higher in larger
aneurysms, but CRP was not associated with expansion
rate. Vainas et al,19 however, showed a modest correlation
of plasma hs-CRP levels with aneurysm size (r 0.47) and
suggested that CRP produced in vascular tissue might
contribute to aneurysm formation.
Our results reveal that there is a statistical association
between hs-CRP levels and the transversal diameter in
asymptomatic, degenerative AAAs. This association sup-
ports the possibility that it has pathogenic factors in com-
mon with occlusive arteriosclerotic disease, based on a
chronic systemic inflammatory response. Moreover, some
authors suggest that hs-CRP plasma levels could be used as
markers of aneurysmal disease.20
Further evidence to consider when establishing a rela-
Table III. Multivariate age-adjusted associations in relatio
Variable
AA
Rapid expand
4.1
(n  130)
No. (%)a
Initial AAA size
47 mm 26 (20)
47 mm 104 (80)
Increasing in hs-CRP
1.4 mg/L 44 (33)
1.4 mg/L 86 (66)
Baseline hs-CRP
4.23 mg/L 57 (44)
4.23 mg/L 73 (56)
12-month hs-CRP
5.7 mg/L 61 (47)
5.7 mg/L 69 (53)
Hypertension 98 (75)
Hyperlipidemia 26 (20)
Diabetes 25 (19)
Smoking 103 (79)
Chronic lower limb ischemia 26 (20)
Heart disease 47 (36)
Cerebrovascular disease 20 (15)
AAA, Abdominal aortic aneurysm; CI, confidence interval; hs-CRP, high-se
aThe value in parentheses represents the percentage of patients in each groutionship that could play a clear role in the etiopathogenic hrocesses of aneurysmal disease and that would associate it
ith chronic inflammatory conditions is the high hs-CRP
lasma level obtained in our study compared with levels
ublished in studies of healthy individuals.22
An important finding in our study was the strong
ssociation (r  0.69; P .05) between aneurysmal diam-
ter and plasma levels among the participants. Despite this
nd that hs-CRP has been shown to be a strong and
ndependent risk factor for cardiovascular complica-
ions,11-15 the data obtained from our research and from
hose of Norman et al17 do not allow us to assert with
bsolute certainty that the hs-CRP baseline level is a pre-
ictive marker of aneurysmal growth or that it is of prog-
ostic value of rupture in AAA patients. In the analysis of
isk factors for aneurysmal expansion, the only two variables
hat were independently associated were the initial aortic
iameter and the rise of CRP level 1.4 mg/L.
The post hoc analysis performed to control the poten-
ial confounding between the AAA diameter and the CRP
evel revealed that the inflammatory status, measured by
ariation of CRP plasma levels and the basal AAA size are
wo independent factors that have been shown to predict
AA expansion. The clinical utility of these results is to
ighlight the usefulness of determinations of hs-CRP levels
s a clinical tool for AAA surveillance, independently of the
AA size monitoring. This will lead us to obtain, with the
ppropriate trials, a cutoff of the level of CRP increase that
ould help us to better predict and, subsequently, to en-
annual expansion rate 4.1 mm
ameter expansion
OR (95% CI)
Slow expanders
4.1
(n  130)
No. (%)a
106 (82) 1 (reference)
24 (18) 6.3 (3.1-7.5)
86 (66) 1 (reference)
44 (33) 3.4 (2.1-5.6)
80 (61.5) 1 (reference)
50 (38.5) 1.9 (0.9-2.8)
78 (60) 1 (reference)
52 (40) 1.8 (0.8-2.5)
91 (70) 1.2 (0.6-1.7)
27 (21) 0.9 (0.7-1.4)
21 (16) 1.1 (0.8-1.6)
90 (69) 1.3 (0.7-1.8)
33 (25) 0.8 (0.5-1.5)
38 (29) 1.1 (0.7-1.4)
21 (16) 0.9 (0.8-1.1)
e C-reactive protein; OR, odds ratio.n to
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Volume 56, Number 1 De Haro et al 51AAA expansion, which is, ultimately, a surrogate marker of
rupture risk.
We urge that measurements of hs-CRP levels to assess
the CRP gradient be a tool in common use as part of
standard practice in AAA surveillance. This CRP gradient
determination joins the AAA diameter as a rupture risk
surrogate to plan earlier repeat surveillance or early surgical
or endovascular AAA repair.
The importance of the initial aortic diameter in subse-
quent AAA expansion has been shown in other population-
based studies.23-26 The diameter of the AAA is a surrogate
marker of the growth rate that reflects the magnitude of the
degenerative process of the wall and thus becomes a surro-
gate marker of rupture. But this surrogate is not enough, or
we could evenmore optimize, if possible, the risk of rupture
assessing to predict which small AAAs are more likely to
require later intervention. In this way, intervention could
perhaps be offered earlier, with less procedure-related mor-
bidity and death, given that age is one of the major risk
factors of these. Fatal ruptures during surveillance could
thus be limited, which would aid our efforts to limit the
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Fig 5. A, No evident correlation was evident between basal ab-
dominal aortic aneurysm (AAA) diameters and the relative rate of
AAA expansion (r 0.31; P .05). B, Significant correlation was
shown between the relative rate of C-reactive protein (CRP)
variation and the relative rate of AAA diameter variation (r 0.62;
P  .05).mortality rate of AAA rupture. aThe assessment of the CRP level increase, once it has
een shown to be an independent expansion risk marker,
an provide a useful clinical tool in the AAA surveillance
nd repair indication for patients with a higher risk of
xpansion and, therefore, of rupture. Obvious ethical issues
n current health care prevent the design of a study that
ould directly clear the predictive power of a marker for the
isk of AAA rupture without indirectly setting this relation-
hip through the risk of AAA expansion. Hence, any study
esign that does not choose the rate of AAA expansion as a
uestionless marker for risk of rupture should be rejected,
lthough this relationship could be reviewed in the future.
evertheless, nowadays, we do not have the necessary
esources that allow us to directly check the predictive value
f any test without deeply violating ethical principles.
The indication for elective repair is mainly based on the
aximal diameter of AAA 5.5 cm.24,25 Consequently,
he benefit of early diagnosis of AAAs by ultrasound screen-
ng is limited. Most of AAAs are too small for intervention
t the time of diagnosis, and even though small AAAs do
upture occasionally, there is currently no well-established
edical treatment for small AAAs. However, two large
andomized trials showed a strategy of early AAA repair was
nefficient.24,25 In addition, only half of the large AAAs we
perate on would rupture if they were left untreated.
Norman et al,17 among others, failed to confirm CRP
evels as surrogate of AAA expansion. Otherwise, we did
nd that neither that nor the CRP baseline levels, but the
ate of increase of CRP plasma levels at a given time, might
e an indicator for the risk that the disease will progress or
s in progress. This parameter could, besides the size,
redict an increased risk of AAA progression and eventual
ater rupture.
To ensure optimum accuracy, we designed a study in
hich all AAA diameter measurements were performed by
TA scan. Use of CT as a surveillance tool is not standard
linical practice, but the lack of precision of the ultrasound
can measurements and between different measurements,
ade it advisable to plan measurements at baseline and at
ollow-up visit with a CT scan “per protocol.” In any case,
ur findings may be related and applied to the more usual
linical practice of ultrasound-based surveillance. In this
cenario, the CRP gradient will contribute to the ultra-
ound scan, providing a tool for better predicting AAA
xpansion.
The lack of association of CRP and other increased
aseline levels of circulation inflammatory markers with the
ate of expansion of AAAs4 raised the possibility that in-
ammation was a response to expansion rather than the
rimary cause, to the point that some authors17 have stated
hat the efforts to pharmacologically control inflammation
ere unlikely to be successful in reducing rates of expan-
ion. The results of our study come to re-establish inflam-
ation as a potential pathogenic pathway and reconsider its
ausal role in the expansion of AAAs. This may thus reopen
ossibilities for pharmacologic inhibition of growth and
rovide a tool for monitoring this inhibition as well as the
doption of this improved risk model in which sequential
11
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planning surveillance of small AAAs and could also indicate
the optimal intervals between the surveillance visits.
CONCLUSIONS
The results obtained in our study confirm a statistical
association between AAA diameter and hs-CRP plasma
levels. This acute-phase marker is produced in chronic
systemic inflammatory states and could be found in the
origin of this disease, causing damage to the media and
producing the resulting arterial dilatation, whereas it would
cause the formation of the arteriosclerotic plaque in occlu-
sive arterial disease. The cohort study corroborates this
potential causal association and contributes with the value
of hs-CRP plasma levels gradient as a marker of disease
progression and rate of expansion.
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